Histone deacetylase 2 is upregulated in normal and keloid scars

Journal of Investigative Dermatology

Volumn 132, Issue 4, 2012, Pages 1293-1296

  O'Connor, Edmund J Fitzgerald ^a   Badshah, Irbaz I ^b   Addae, Lucy Y ^b   Kundasamy, Preeya ^b   Thanabalasingam, Sukanthini ^b   Abioye, Daniel ^b   Soldin, Mark ^a   Shaw, Tanya J ^b  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVOTERMIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ANTIINFLAMMATORY ACTIVITY; CELL CULTURE; CELL DENSITY; CELL DIFFERENTIATION; CELL GROWTH; FIBROBLAST; HUMAN; IMMUNOHISTOCHEMISTRY; KELOID; LETTER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCAR; SKIN FIBROSIS; UPREGULATION; WESTERN BLOTTING;

EID: 84858297477     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.432     Document Type: Letter

References (15)

1. Bhattacharyya S, Ghosh AK, Pannu J et al. (2005) Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to TGFbeta. Arthritis Rheum 52: 1248-58
2. Brown BC, McKenna SP, Siddhi K et al. (2008) The hidden cost of skin scars: Quality of life after skin scarring. J Plast Reconstr Aesthet Surg 61:1049-58
3. Diao JS, Xia WS, Yi CG et al. (2011) Trichostatin A inhibits collagen synthesis and induces apoptosis in keloid fibroblasts. Arch Dermatol Res 303:573-80
4. Glenisson W, Castronovo V, Waltregny D (2007) Histone deacetylase 4 is required for TGFbeta1- induced myofibroblastic differentiation. Biochim Biophys Acta 1773:1572-82
5. Han SB, Lee JK (2009) Anti-inflammatory effect of Trichostatin-A on murine bone marrowderived macrophages. Arch Pharm Res 32:613-24
6. Iyer A, Fenning A, Lim J et al. (2010) Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol 159:1408-17
7. Kuo MH, Allis CD (1998) Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20:615-25
8. Li HL, Liu C, de Couto G et al. (2008) Curcumin prevents and reverses murine cardiac hypertrophy. J Clin Invest 118:879-93
9. Mannaerts I, Nuytten NR, Rogiers V et al. (2010) Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology 51:603-14
10. Marumo T, Hishikawa K, Yoshikawa M et al. (2010) Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury. Am J Physiol Renal Physiol 298:F133-41
11. Pang M, Kothapally J, Mao H et al. (2009) Inhibition of HDAC activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 297:F995
12. Paris M, Porcelloni M, Binaschi M et al. (2008) Histone deacetylase inhibitors: From bench to clinic. J Med Chem 51:1505-29
13. So K, McGrouther DA, Bush JA et al. (2011) Avotermin for scar improvement following scar revision surgery: A randomized, doubleblind, within-patient, placebo-controlled, phase II clinical trial. Plast Reconstr Surg 128(1):163-72
14. Sund B (2000) New Developments in Wound Care. London: PJB Publications
15. Wolfram D, Tzankov A, Pulzl P et al. (2009) Hypertrophic scars and keloids-A review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg 35: 171-81